An uncontrolled study of 37 consenting patients with SLE claims that subcutaneous administration of recombinant IL-2 every other day for 2 weeks decreased SLEDAI, Th17, Tfh, and DN T cells, and increased Treg cell numbers (222). Here, IL2 is linked to systemic lupus erythematosus.